More efficient clinical trials in pancreatic cancer: develop better treatment options, faster

Abstract

Clinical development of new treatment options for patients with pancreatic cancer has been slow and expensive and resulted in few effective therapies. With a dismal five-year survival rate of 11% in the U.S., pancreatic cancer remains the third leading cause of cancer-related deaths and is poised to move to second by 2030. Standard clinical trials typically compare one investigational treatment to one standard of care, encompass one phase of clinical investigation at a time, and treat one patient population. Accrual and data analysis are often very slow, and unfortunately, the vast majority of clinical trials targeting pancreatic cancer patients are unsuccessful. More efficient clinical trial designs can include combining phases I and II or phases II and III, and trials that involve a master protocol approach can also answer multiple clinical questions simultaneously. These modern clinical trial designs can allow a faster, more efficient and cost-effective approach to testing investigational therapies in patients with pancreatic cancer and, most importantly, fewer patients may be required to determine the efficacy of treatment. Herein we summarize some of the recent innovative clinical trials in pancreatic cancer to provide meaningful data toward developing new treatment options to benefit patients with a dismal disease like pancreatic cancer.

Keywords

Pancreatic ductal adenocarcinoma / clinical trials / master protocols / platform trials

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] Siegel RL,Fuchs HE.Cancer statistics, 2021.CA Cancer J Clin2021;71:7-33

[3] Rahib L,Matrisian LM.Estimated projection of US cancer incidence and death to 2040.JAMA Netw Open2021;4:e214708 PMCID:PMC8027914

[4] Nevala-Plagemann C,Garrido-Laguna I.From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.Nat Rev Clin Oncol2020;17:108-23

[5] Hoos WA,Rahib L,Fleshman JM.Pancreatic cancer clinical trials and accrual in the United States.J Clin Oncol2013;31:3432-8

[6] Rahib L,Matrisian LM.Evaluation of pancreatic cancer clinical trials and benchmarks for clinically meaningful future trials: a systematic review.JAMA Oncol2016;2:1209-16

[7] Matrisian LM.The past, present, and future of pancreatic cancer clinical trials.Am Soc Clin Oncol Educ Book2016;35:e205-15

[8] Sertkaya A,Berlind A. Examination of clinical trial costs and barriers for drug development, In: Report HHSP23337007T, Department of Health and Human Services (HHS): Washington USA. 2014.

[9] Matrisian LM,Moravek C.Trends in pancreatic cancer clinical trials in the United States.Med Res Arch2021;

[10] Woodcock J.Master protocols to study multiple therapies, multiple diseases, or both.N Engl J Med2017;377:62-70

[11] Seligson ND,Ragg S.Developing drugs for tissue-agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine.Clin Pharmacol Ther2021;109:334-42 PMCID:PMC7891377

[12] Golan T,Reni M.Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.N Engl J Med2019;381:317-27 PMCID:PMC6810605

[13] Burris HA 3rd,Andersen J.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J Clin Oncol1997;15:2403-13

[14] Conroy T,Ychou M.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med2011;364:1817-25

[15] Von Hoff DD,Arena FP.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.N Engl J Med2013;369:1691-703 PMCID:PMC4631139

[16] Wang-gillam A,Bodoky G.Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.Lancet2016;387:545-57

[17] Neoptolemos JP,Ghaneh P.Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.Lancet2017;389:1011-24

[18] Conroy T,Hebbar M.FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.N Engl J Med2018;379:2395-406

[19] Drilon A,Kummar S.Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children.N Engl J Med2018;378:731-9 PMCID:PMC5857389

[20] Doebele RC,Paz-ares L.Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.Lancet Oncol2020;21:271-82 PMCID:PMC7461630

[21] Marabelle A,Lopez J.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol2020;21:1353-65

[22] Le DT,Smith KN.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science2017;357:409-13 PMCID:PMC5576142

[23] FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors, 2021. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors [Last accessed on 13 Oct 2022].

[24] Salama AKS,Macrae ER.Dabrafenib and trametinib in patients with tumors with BRAF^V600E mutations: results of the NCI-MATCH trial subprotocol H.J Clin Oncol2020;38:3895-904 PMCID:PMC7676884

[25] Hendifar A,Wolpin B.Retrospective case series analysis of RAF family alterations in pancreatic cancer: real-world outcomes from targeted and standard therapies.JCO Precis Oncol2021;5:PO PMCID:PMC8407652

[26] Waddell N,Patch AM.Whole genomes redefine the mutational landscape of pancreatic cancer.Nature2015;518:495-501 PMCID:PMC4523082

[27] Genome Atlas Research Network. Electronic address, Cancer genome atlas research network. integrated genomic characterization of pancreatic ductal adenocarcinoma.Cancer Cell2017;32:185-203.e13

[28] Pishvaian MJ,Brody JR.Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.Lancet Oncol2020;21:508-18 PMCID:PMC7453743

[29] Pishvaian MJ,Halverson D.Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative.Clin Cancer Res2018;24:5018-27

[30] Aung KL,Denroche RE.Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial.Clin Cancer Res2018;24:1344-54 PMCID:PMC5968824

[31] Chan-Seng-Yue M,Wilson GW.Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution.Nat Genet2020;52:231-40

[32] Dreyer SB,Cooke SL.PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer.Clin Oncol2020;32:1-4

[33] Barker AD,Kelloff GJ,Berry DA.I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.Clin Pharmacol Ther2009;86:97-100

[34] Alexander BM,Berger MS.Adaptive global innovative learning environment for glioblastoma: GBM AGILE.Clin Cancer Res2018;24:737-43

[35] Douglas JE,Ma J.PIONEER-panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer.BMC Cancer2022;22:14 PMCID:PMC8722115

[36] Moore MJ,Hamm J.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol2007;25:1960-6

[37] Van Cutsem E,Bennouna J.Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.J Clin Oncol2009;27:2231-7

[38] Lawlor RT,Mafficini A.Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions.Cancers2021;13:3119 PMCID:PMC8269341